Compound: Desvenlafaxine
SMILES: Oc1ccc(C(C2(O)CCCCC2)CN(C)C)cc1
InChIKey: KYYIDSXMWOZKMP-UHFFFAOYSA-N
Synonyms: Desvenlafaxine, 93413-62-8, O-Desmethylvenlafaxine, 4-(2-(Dimethylamino)-1-(1-hydroxycyclohexyl)ethyl)phenol, 4-[2-(Dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol, Khedezla, Newven, Mdd-xr, Desvenlafaxina, NG99554ANW, CHEBI:83527, DTXSID40869118, Phenol, 4-(2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl)-, Phenol, 4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]-, desvenlafaxinum, O desmethylvenlafaxine, RefChem:57728, DTXCID00216346, N06AX23, 700-516-2, O-desmethyl venlafaxine, DVS 233, D,L-O-Desmethyl Venlafaxine, D-veniz, MFCD00871934, Desvenlafaxine (INN), Desvenlafaxine [INN], O-DESMETHYLVENLAFAXINE (ODV), 1-[2-(dimethylamino)-1-(4-hydroxyphenyl)ethyl]cyclohexanol, Desvenlafaxine [INN:BAN], ODV, Venlafaxine O-Desmethyl, D,L-O-Desmethyl Venlafaxine (100 ug/mL in Methanol), UNII-NG99554ANW, O-Desvenlafaxine, HSDB 7993, 93413-62-8 (free base), Khedezla (TN), O-Desmethylvenlafaxine; 4-[2-(Dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol; D-VENIZ; DVS 233; Desvenlafaxine; Pristiq, O-desmethyl-venlafaxine, DESVENLAFAXINE [MI], EC 700-516-2, CHEMBL1118, D,L O-Desmethyl Venlafaxine, SCHEMBL34864, MLS006010042, DESVENLAFAXINE [VANDF], GTPL7158, orb1308104, orb3141373, SCHEMBL1133549, DESVENLAFAXINE [USP-RS], DESVENLAFAXINE [WHO-DD], Venlafaxine O-Desmethyl Impurity, BDBM86748, HMS3652K16, HMS3885F05, HMS5082E16, HY-B0602, MSK10512, DESVENLAFAXINE [ORANGE BOOK], EBC-13155, PDSP1_001804, PDSP2_001787, s4113, DESVENLAFAXINE [USP MONOGRAPH], AKOS015896311, CCG-267081, DB06700, DS-1282, SB17444, NSC_6918664, NCGC00345883-04, NCGC00345883-07, DA-76384, SMR004701214, O-Desmethylvenlafaxine, analytical standard, O-Desmethylvenlafaxine, 1mg/ml in Methanol, CAS_386750-22-7, D5598, NS00000330, SW219514-2, O-Desmethylvenlafaxine 0.1 mg/ml in Methanol, D07793, AB01563022_01, EN300-7353726, F079439, Q2419445, BRD-A98845662-001-02-3, BRD-A98845662-001-03-1, BRD-A98845662-036-02-9, BRD-A98845662-036-03-7, BRD-A98845662-036-04-5, Venlafaxine O-desmethyl 100 microg/mL in Acetonitrile, Z1741977125, 1-[2-dimethylamino-1-(4-hydroxyphenyl)ethyl]cyclohexanol, 4-(2-(Dimethylamino)-1-(1-hydroxycyclohexyl)-ethyl)phenol, 4-[2-(Dimethylamino)-1-(1-hydroxycyclo-hexyl)ethyl]phenol, 4-[2-(Dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol #, (RS)-1-[2-(dimethylamino)-1-(4-hydroxyphenyl)ethyl]cyclohexanol
Theoretical properties:
molecular_formula: C16H25NO2
molecular_weight: 263.37 g/mol
exact_mass: 263.188529040 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 2
hydrogen_bond_acceptor_count: 3
rotatable_bond_count: 4
heavy_atom_count: 19
topological_polar_surface_area: 43.7 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
pubchem: O-desmethylvenlafaxine is a tertiary amino compound that is N,N-dimethylethanamine substituted at position 1 by a 1-hydroxycyclohexyl and 4-hydroxyphenyl group. It is a metabolite of the drug venlafaxine. It has a role as an antidepressant, a drug metabolite and a marine xenobiotic metabolite. It is a member of cyclohexanols, a member of phenols and a tertiary amino compound.
chebi: A tertiary amino compound that is <em>N</em>,<em>N</em>-dimethylethanamine substituted at position 1 by a 1-hydroxycyclohexyl and 4-hydroxyphenyl group. It is a metabolite of the drug venlafaxine.
chembl: DESVENLAFAXINE is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Desvenlafaxine, sold under the brand name Pristiq among others, is a medication used to treat depression. It is an antidepressant of the serotonin–norepinephrine reuptake inhibitor (SNRI) class and is taken by mouth. It is recommended that the need for further treatment be occasionally reassessed. Studies have shown similar effectiveness compared to its parent compound venlafaxine. 
Common side effects include dizziness, trouble sleeping, increased sweating, constipation, sleepiness, anxiety, and sexual problems. In some patients, sexual dysfunction may persist even after the drug is discontinued, a condition known as post-SSRI sexual dysfunction; regulatory agencies including the European Medicines Agency and Health Canada have recommended that desvenlafaxine's product labeling warn of this risk. Serious side effects may include suicide in those under the age of 25, serotonin syndrome, bleeding, mania, and high blood pressure.
Desvenlafaxine was approved for medical use in the United States in 2008. In Europe its application for use was denied in 2009, although has since been approved for Spain and Germany. In 2023, it was the 189th most commonly prescribed medication in the United States, with more than 2 million prescriptions.